[Anti-VEGF therapy of wet age-related macular degeneration: analysis of patients lost to follow-up].

Unlabelled: Patients lost to follow-up (LTFU) are a well-recognized challenge, both in clinical trials and in real clinical practice.

Purpose: To study the reasons for patients receiving anti-VEGF therapy for «wet» age-related macular degeneration (wAMD) in clinical environment to cease monitoring in the clinic.

Material And Methods: This retrospective cohort study included patients with wAMD which received anti-VEGF therapy (ranibizumab, aflibercept) in the Ural State Medical University clinic from 2011 to 2019 (=241).